Trial · NCT04956432
A Multicentre, Randomized, Double-blind, Allopurinol Controlled Study to Evaluate the Efficacy and Safety of SHR4640 in Subjects With Gout
NCT04956432, Phase 3, Completed, Jiangsu HengRui Medicine Co., Ltd.
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. A Multicentre, Randomized, Double-blind, Allopurinol Controlled Study to Evaluate the Efficacy and Safety of SHR4640 in Subjects With Gout. Trials, record NCT04956432. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04956432
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Multicentre, Randomized, Double-blind, Allopurinol Controlled Study to Evaluate the Efficacy and Safety of SHR4640 in Subjects With Gout
- NCT number
- NCT04956432
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 779 participants, actual
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Conditions
- Gout
- Interventions
- SHR4640, Allopurinol
- First posted
- 2021-07-09
- Last updated
- 2025-01-24
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportion of subjects with a serum uric acid level≤360 μmol/L | Start of Treatment to end of study (approximately 16 weeks) | |
| Secondary | Percentage change in serum uric acid from baseline at each visit during 16 weeks of treatment | Start of Treatment to end of study (approximately 16 weeks) | |
| Secondary | Absolute changes in serum uric acid from baseline at each visit during 16 weeks of treatment | Start of Treatment to end of study (approximately 16 weeks) | |
| Secondary | The proportion of subjects with A serum uric acid level≤ 360 μmol/L at each visit within 16 weeks of treatment | Start of Treatment to end of study (approximately 16 weeks) | |
| Secondary | Percentage change of serum uric acid from baseline at each visit within 52 weeks of treatment | Start of Treatment to end of study (approximately 52 weeks) | |
| Secondary | change value of serum uric acid from baseline at each visit within 52 weeks of treatment | Start of Treatment to end of study (approximately 52 weeks) | |
| Secondary | proportion of subjects with serum uric acid ≤ 360 μmol/L at each visit within 52 weeks of treatment | Start of Treatment to end of study (approximately 52 weeks) | |
| Secondary | serum uric acid value at each visit within 52 weeks of treatment | Start of Treatment to end of study (approximately 52 weeks) |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04956432
GET https://conductscience.org/api/trials/v1/NCT04956432/registered